Amgen reports good interim safety and efficacy results from Phase II trial of Xgeva

Biotechnology company Amgen has reported planned interim safety and efficacy results from Phase II trial of a fully human monoclonal antibody, Xgeva (denosumab), in patients with giant cell tumour of bone (GCTB).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news